The Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics (PACT) Act, signed into law August 10, 2022, represented the largest expansion of VA toxic exposure presumptives in the agency's history. Among the conditions added to VA's presumptive list were multiple genitourinary cancers — conditions affecting the urinary tract and male reproductive organs.
The scientific rationale for including GU cancers in the PACT Act is rooted in well-established research on occupational carcinogen exposure. The carcinogens in burn pit smoke — polycyclic aromatic hydrocarbons (PAHs), benzene, formaldehyde, dioxins, heavy metals — are known urinary tract carcinogens. Many are excreted through the kidneys and concentrated in the urine, exposing the bladder epithelium to sustained carcinogen contact. The epidemiological literature on bladder and kidney cancer risk in workers exposed to similar combustion byproducts (firefighters, petroleum workers, dye industry workers) supports the biological plausibility of the PACT Act's coverage decisions.
The Act does not require veterans to prove this scientific chain — the legislative determination that these exposures cause these cancers is built into the law. But understanding why genitourinary cancers were included helps veterans and their representatives make the case for service connection when needed and claim the full scope of residual conditions from treatment.
| Cancer Type | VA Diagnostic Code | Also Agent Orange? | Rating During Treatment |
|---|---|---|---|
| Bladder cancer (urothelial/transitional cell) | DC 7528 | ✓ Yes (since 2021) | 100% |
| Testicular cancer (germ cell, seminoma, non-seminoma) | DC 7524 | Not specifically | 100% |
| Kidney cancer (renal cell carcinoma / hypernephroma) | DC 7529 | Not specifically | 100% |
| Ureter cancer (transitional cell) | DC 7528 / GU series | Not specifically | 100% |
| Prostate cancer | DC 7528 (prostate) | ✓ Yes (since 2001) | 100% |
| Urethral cancer | DC 7517 / GU series | Not specifically | 100% |
All of these cancers share the common feature of being rated at 100% during active treatment and requiring re-evaluation for residual disability after the six-month post-treatment evaluation period. The specific residuals — and how they're rated — differ significantly by cancer type and treatment approach.
PACT Act genitourinary cancer presumptives apply to veterans who meet the following service requirements:
Bladder cancer specifically also qualifies under the Agent Orange presumptive (38 CFR § 3.309(e)) for veterans who served in Vietnam, Korea DMZ, Thailand, or other Agent Orange-covered locations. This dual pathway means bladder cancer veterans may have the most favorable claim options.
Reserve component members who were called to active duty and deployed to PACT Act-covered locations are eligible for the same presumptives as regular active duty veterans. Guard and Reserve members who served on active orders (Title 10) at covered locations qualify. Members who were never activated to qualifying locations may not qualify under the PACT Act's active duty deployment requirement.
VA's approach to rating genitourinary cancers follows a two-phase framework that applies uniformly across all cancer types:
Any malignant GU cancer that is under active treatment receives a 100% rating. "Active treatment" includes surgery, chemotherapy, radiation, immunotherapy, targeted therapy, and active surveillance protocols. The 100% rating is not based on severity — it is categorical and automatic upon diagnosis with treatment.
Six months after treatment ends, VA schedules a C&P evaluation to determine a residuals rating. This is where understanding the specific DC codes and rating criteria for your cancer type becomes critical — and where many veterans are significantly underrated.
The residuals rating is determined by:
Bladder cancer is the most common PACT Act genitourinary cancer and the only GU cancer also covered by the Agent Orange presumptive. Key points:
→ Full Guide: Bladder Cancer VA Disability Claim: Agent Orange & PACT Act (2026)
Testicular cancer is most prevalent in veterans under 40 — the same age group most likely to have served in OEF/OIF/OND deployments near burn pits. The PACT Act specifically created a presumptive pathway for these younger veterans.
→ Full Guide: Testicular Cancer VA Disability Claim: PACT Act Presumptive (2026)
Renal cell carcinoma (RCC) — the most common kidney cancer in adults — is covered by the PACT Act's GU cancer presumptive. Kidney cancer claims have unique rating considerations because the kidneys are bilateral organs and partial or complete removal (nephrectomy) affects renal function in specific ways.
| Phase | Rating |
|---|---|
| Active kidney cancer (under treatment) | 100% |
| Six-month post-treatment evaluation | 100% |
| Post-nephrectomy residuals (one kidney) | Rated under renal function codes |
| Reduced kidney function (GFR-based) | 0–100% based on creatinine/GFR level |
| Dialysis dependence (both kidneys affected) | 100% |
After nephrectomy (surgical removal of one kidney), VA rates residual kidney function under DC 7530 (renal dysfunction). Ratings are based on:
Veterans who develop renovascular hypertension — high blood pressure caused by reduced kidney function from nephrectomy or partial nephrectomy — should file for hypertension as a secondary condition under DC 7101. This is frequently missed but can add 10–60% to the combined rating.
Advanced or metastatic kidney cancer often requires systemic therapy:
Ureteral cancer (transitional cell carcinoma of the ureter) is among the rarer PACT Act-covered GU cancers, but it shares the same toxicological mechanism as bladder cancer — concentrated carcinogens in urine bathing the urothelial lining. VA rates ureter cancer using the genitourinary malignant neoplasm framework, similar to DC 7528.
Treatment for ureteral cancer typically involves ureterectomy (surgical removal of the affected ureter) often combined with nephrectomy (kidney removal) for proximal tumors — creating a compound surgical result that involves both the kidney and ureter. Veterans with ureter cancer should claim:
Veterans who develop more than one genitourinary cancer — which can occur when carcinogen exposure affects multiple organs of the urinary tract — are entitled to separate service connection and separate ratings for each cancer.
If you've been diagnosed with both bladder cancer and kidney cancer, you file separate claims for each. VA rates each independently and applies combined ratings calculations. Do not assume that one cancer "covers" the other — the residuals of each are rated separately and can compound your total disability significantly.
Veterans with multiple GU cancers may also be at elevated risk for developing secondary malignancies — cancers that arise as a result of prior treatment with chemotherapy or radiation. If you develop a new cancer after treating a service-connected GU cancer, consult with a VA-accredited attorney about claiming the new cancer as secondary to the service-connected condition and its treatment.
Across all PACT Act genitourinary cancers, certain secondary conditions appear frequently and are often left unclaimed:
The PACT Act filing process for GU cancers follows standard VA procedures with a few key details:
Gather your DD-214 and any deployment orders that document service at a PACT Act-covered location (Iraq, Afghanistan, Kuwait, etc., after August 2, 1990). If you served in Vietnam or other Agent Orange-covered locations, bladder cancer may qualify under the Agent Orange pathway as well.
List each cancer as a separate disability. For each, specify: "[Cancer type] — PACT Act presumptive due to toxic exposure during service in [location] [dates]." List all secondary conditions separately.
The effective date for your claim is the date VA receives it. Filing today vs. waiting three months can mean thousands of dollars in back pay. You can file a complete claim or file an Intent to File (ITF) form first to lock in your effective date while gathering records.
For detailed guidance on each specific cancer type, see:
Check Your GU Cancer Claim Eligibility
PACT Act genitourinary cancer presumptives are powerful — no nexus letter required. Our free claim review connects you with VA-accredited attorneys who handle cancer claims from diagnosis through residuals.
Check My Eligibility — Free →Editorial Standards: Written by Marcus J. Webb, veterans benefits researcher. Verified against DC 7524/7528/7529 and PACT Act provisions. Last reviewed: July 2026. Not legal advice — for representation, connect with a VA-accredited attorney.
Genitourinary cancers are PACT Act presumptive — no nexus letter required. File now to protect your effective date.
Start My Free Claim Review — No Phone Required →